06.09.20

Oxford Biomedica Snags Manufacturing Equipment to Ramp Up Production of COVID-19 Vaccine

Source: FiercePharma

In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca’s manufacturing partners has struck a deal for new equipment, according to a FiercePharma report.

Oxford Biomedica has inked a five-year deal with the U.K.’s Vaccines Manufacturing and Innovation Centre (VMIC) to build out the CDMO’s Oxbox facility to help produce doses of the university’s adenovirus-based COVID-19 vaccine. 

Read the full article.

Related Content